HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 231 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.38 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $15,280,000 | -34.8% | 400,000 | -34.9% | 0.04% | -34.0% |
Q1 2023 | $23,448,660 | +26.2% | 614,000 | +88.1% | 0.05% | +20.5% |
Q4 2022 | $18,577,850 | -11.6% | 326,500 | -59.2% | 0.04% | -17.0% |
Q3 2020 | $21,024,000 | -21.6% | 800,000 | -20.0% | 0.05% | -23.2% |
Q2 2020 | $26,810,000 | +112.9% | 1,000,000 | +42.9% | 0.07% | +81.6% |
Q1 2020 | $12,593,000 | -36.9% | 700,000 | -37.8% | 0.04% | -22.4% |
Q4 2019 | $19,946,000 | +71.5% | 1,125,000 | +50.0% | 0.05% | +69.0% |
Q3 2019 | $11,633,000 | +50.5% | 750,000 | +66.7% | 0.03% | +52.6% |
Q2 2019 | $7,731,000 | +220.1% | 450,000 | +200.0% | 0.02% | +216.7% |
Q1 2019 | $2,415,000 | -52.3% | 150,000 | -40.0% | 0.01% | -45.5% |
Q4 2017 | $5,065,000 | +16.6% | 250,000 | 0.0% | 0.01% | 0.0% |
Q3 2017 | $4,343,000 | +4.2% | 250,000 | -23.1% | 0.01% | +10.0% |
Q2 2017 | $4,167,000 | +221.5% | 325,000 | +225.0% | 0.01% | +233.3% |
Q1 2017 | $1,296,000 | -45.6% | 100,000 | -46.7% | 0.00% | -57.1% |
Q1 2014 | $2,384,000 | – | 187,584 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |